Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 5Phase NA 4Phase 1 3Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Pancreatic Neoplasms 7Breast Neoplasms 7Colorectal Neoplasms 6Stomach Neoplasms 5Neoplasms 5Sarcoma 3Precision Cell Immunotherapy 3Ovarian Neoplasms 3Neoplasm Metastasis 3Mesothelioma, Malignant 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Hodgkin Disease 3Glioblastoma 3Esophageal Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Mesothelioma 2Melanoma 2Lymphoma 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Ovarian Epithelial 2Virus Diseases 1

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × Drug Therapy × Clear all
NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Chinese PLA General Hospital

Phase 1/2 Recruiting
250 enrolled

Neoplasms, Recurrence

NCT06090864 2025-10-20

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
31 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡